Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling.
The diagnostic of Amyotrophic lateral sclerosis (ALS) remains based on clinical and neurophysiological observations. The actual delay between the onset of the symptoms and diagnosis is about 1 year, preventing early inclusion of patients into clinical trials and early care of the disease. Therefore,...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9a2d498492274d5393a990430a9c586a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9a2d498492274d5393a990430a9c586a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9a2d498492274d5393a990430a9c586a2021-11-18T08:48:16ZPlasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling.1932-620310.1371/journal.pone.0079733https://doaj.org/article/9a2d498492274d5393a990430a9c586a2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24224000/?tool=EBIhttps://doaj.org/toc/1932-6203The diagnostic of Amyotrophic lateral sclerosis (ALS) remains based on clinical and neurophysiological observations. The actual delay between the onset of the symptoms and diagnosis is about 1 year, preventing early inclusion of patients into clinical trials and early care of the disease. Therefore, finding biomarkers with high sensitivity and specificity remains urgent. In our study, we looked for peptide biomarkers in plasma samples using reverse phase magnetic beads (C18 and C8) and MALDI-TOF mass spectrometry analysis. From a set of ALS patients (n=30) and healthy age-matched controls (n=30), C18- or C8-SVM-based models for ALS diagnostic were constructed on the base of the minimum of the most discriminant peaks. These two SVM-based models end up in excellent separations between the 2 groups of patients (recognition capability overall classes > 97%) and classify blinded samples (10 ALS and 10 healthy age-matched controls) with very high sensitivities and specificities (>90%). Some of these discriminant peaks have been identified by Mass Spectrometry (MS) analyses and correspond to (or are fragments of) major plasma proteins, partly linked to the blood coagulation.Laurence ConrauxCatherine PechHalim GuerraouiDenis LoyauxPascual FerraraJean-Claude GuillemotVincent MeiningerPierre-François PradatFrançois SalachasGaëlle BruneteauNadine Le ForestierLucette LacomblezPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 11, p e79733 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Laurence Conraux Catherine Pech Halim Guerraoui Denis Loyaux Pascual Ferrara Jean-Claude Guillemot Vincent Meininger Pierre-François Pradat François Salachas Gaëlle Bruneteau Nadine Le Forestier Lucette Lacomblez Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling. |
| description |
The diagnostic of Amyotrophic lateral sclerosis (ALS) remains based on clinical and neurophysiological observations. The actual delay between the onset of the symptoms and diagnosis is about 1 year, preventing early inclusion of patients into clinical trials and early care of the disease. Therefore, finding biomarkers with high sensitivity and specificity remains urgent. In our study, we looked for peptide biomarkers in plasma samples using reverse phase magnetic beads (C18 and C8) and MALDI-TOF mass spectrometry analysis. From a set of ALS patients (n=30) and healthy age-matched controls (n=30), C18- or C8-SVM-based models for ALS diagnostic were constructed on the base of the minimum of the most discriminant peaks. These two SVM-based models end up in excellent separations between the 2 groups of patients (recognition capability overall classes > 97%) and classify blinded samples (10 ALS and 10 healthy age-matched controls) with very high sensitivities and specificities (>90%). Some of these discriminant peaks have been identified by Mass Spectrometry (MS) analyses and correspond to (or are fragments of) major plasma proteins, partly linked to the blood coagulation. |
| format |
article |
| author |
Laurence Conraux Catherine Pech Halim Guerraoui Denis Loyaux Pascual Ferrara Jean-Claude Guillemot Vincent Meininger Pierre-François Pradat François Salachas Gaëlle Bruneteau Nadine Le Forestier Lucette Lacomblez |
| author_facet |
Laurence Conraux Catherine Pech Halim Guerraoui Denis Loyaux Pascual Ferrara Jean-Claude Guillemot Vincent Meininger Pierre-François Pradat François Salachas Gaëlle Bruneteau Nadine Le Forestier Lucette Lacomblez |
| author_sort |
Laurence Conraux |
| title |
Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling. |
| title_short |
Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling. |
| title_full |
Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling. |
| title_fullStr |
Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling. |
| title_full_unstemmed |
Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling. |
| title_sort |
plasma peptide biomarker discovery for amyotrophic lateral sclerosis by maldi-tof mass spectrometry profiling. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/9a2d498492274d5393a990430a9c586a |
| work_keys_str_mv |
AT laurenceconraux plasmapeptidebiomarkerdiscoveryforamyotrophiclateralsclerosisbymalditofmassspectrometryprofiling AT catherinepech plasmapeptidebiomarkerdiscoveryforamyotrophiclateralsclerosisbymalditofmassspectrometryprofiling AT halimguerraoui plasmapeptidebiomarkerdiscoveryforamyotrophiclateralsclerosisbymalditofmassspectrometryprofiling AT denisloyaux plasmapeptidebiomarkerdiscoveryforamyotrophiclateralsclerosisbymalditofmassspectrometryprofiling AT pascualferrara plasmapeptidebiomarkerdiscoveryforamyotrophiclateralsclerosisbymalditofmassspectrometryprofiling AT jeanclaudeguillemot plasmapeptidebiomarkerdiscoveryforamyotrophiclateralsclerosisbymalditofmassspectrometryprofiling AT vincentmeininger plasmapeptidebiomarkerdiscoveryforamyotrophiclateralsclerosisbymalditofmassspectrometryprofiling AT pierrefrancoispradat plasmapeptidebiomarkerdiscoveryforamyotrophiclateralsclerosisbymalditofmassspectrometryprofiling AT francoissalachas plasmapeptidebiomarkerdiscoveryforamyotrophiclateralsclerosisbymalditofmassspectrometryprofiling AT gaellebruneteau plasmapeptidebiomarkerdiscoveryforamyotrophiclateralsclerosisbymalditofmassspectrometryprofiling AT nadineleforestier plasmapeptidebiomarkerdiscoveryforamyotrophiclateralsclerosisbymalditofmassspectrometryprofiling AT lucettelacomblez plasmapeptidebiomarkerdiscoveryforamyotrophiclateralsclerosisbymalditofmassspectrometryprofiling |
| _version_ |
1718421276889972736 |